This application requests support for the third cycle of this program project that has been dedicated to the development of gene therapy for cardiovascular diseases. We plan in this cycle to focus on the pre-clinical development of gene therapy to liver for the treatment of two severe dyslipidemias: familial hypercholesterolemia (FH) and abetalipoproteinemia (ABL). In studies performed during the current cycle of this grant we developed a number of vectors based on novel adeno-associated viruses (AAV). We showed that many of these have substantially improved performance profiles in terms of gene transfer efficiency, safety and immunogenicity. The goal of this application is to identify the optimal AAV vector for liver directed gene therapy and to study areas of vector biology relevant for the potential testing of these vectors in humans. The feasibility of treating FH and ABL will be assessed in relevant animal models. Key milestones are identification of the clinical candidate vector in year one and the development of sufficient pre-clinical data at the end of year 5 to proceed with phase I clinical trials in both FH and/or ABL in a subsequent application. Project I, directed by Dr. J. Wilson, will develop the clinical candidate vector and will evaluate key issues of vector immunology relevant to safety and efficacy. Project II, directed by Dr. D. Rader, will perform all pre-clincal studies of gene therapy in animals models of FH (mice, rabbits and monkeys) and ABL (mice). Project III, directed by Dr. G. Gao, will evaluate the molecular biology of AAV in liver in terms of recombination with endogenous virus, integration and oncogenicity. The Projects will be supported by three scientific cores - Vector (Core A), Cell Morphology (Core B), and Animal Models (Core C) - and the Administrative Core (Core D). Lay abstract. This project will use a novel viral vector system based on adeno-associated viral vectors (AAV) to develop gene therapy for two very severe inherited forms of lipid metabolism called: familial hypercholesterolemia (FH) and abetalipoproteinemia (ABL). The grant will do all pre-clinical studies necessary to begin clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL059407-14
Application #
8300925
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Skarlatos, Sonia
Project Start
2000-05-15
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
14
Fiscal Year
2012
Total Cost
$1,918,033
Indirect Cost
$556,498
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Liu, Lijun; Nam, Minwoo; Fan, Wei et al. (2014) Nutrient sensing by the mitochondrial transcription machinery dictates oxidative phosphorylation. J Clin Invest 124:768-84
Mikals, Kyle; Nam, Hyun-Joo; Van Vliet, Kim et al. (2014) The structure of AAVrh32.33, a novel gene delivery vector. J Struct Biol 186:308-17
Wang, Dan; Zhong, Li; Nahid, M Abu et al. (2014) The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11:345-64
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med 18:67-77
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med 18:151-61
Lock, Martin; Alvira, Mauricio R; Chen, Shu-Jen et al. (2014) Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Hum Gene Ther Methods 25:115-25
Gao, Kai; Li, Mengxin; Zhong, Li et al. (2014) Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side-Effects. Mol Ther Methods Clin Dev 1:20139
Somanathan, Suryanarayan; Jacobs, Frank; Wang, Qiang et al. (2014) AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia. Circ Res 115:591-9
Kassim, Sadik H; Li, Hui; Bell, Peter et al. (2013) Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther 24:19-26
Gruntman, Alisha M; Bish, Lawrence T; Mueller, Christian et al. (2013) Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol Chapter 14:Unit 14D.3

Showing the most recent 10 out of 126 publications